InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today reported its financial results for fiscal year 2024, ended June 30, 2024. The company also provided a business update on its pharmaceutical development programs and its strengthened patent portfolio, as well as the sustained revenue growth experienced by its wholly owned subsidiary BayMedica.
Key financial and operating highlights as of June 30, 2024, included cash, cash equivalents, and short-term investments of $6.6 million; a net loss of $7.7 million compared to $7.9 million in fiscal 2023; advancement of the INM-901 Alzheimer’s disease program with long-term preclinical studies; and launch of the INM-089 preclinical program in the treatment of Age-Related Macular Degeneration (“AMD”). The company also noted that it had received three U.S. patents and that the total sales for BayMedica increased by 11% over the previous fiscal year to $4.6 million in fiscal 2024.
To view the full press release, visit https://ibn.fm/lBEhw
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with its subsidiary, BayMedica, InMed is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates. For more information, visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN